Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank.

Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller HJ, Dean B.

Int J Neuropsychopharmacol. 2015 Apr 21;18(10):pyv042. doi: 10.1093/ijnp/pyv042. Review.

2.

Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.

Dean B, Moller HJ, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ.

Int J Neuropsychopharmacol. 2014 Jan;17(1):137-48. doi: 10.1017/S1461145713001077. Epub 2013 Sep 24.

PMID:
24063634
3.

The potential of biomarkers in psychiatry: focus on proteomics.

Sokolowska I, Ngounou Wetie AG, Wormwood K, Thome J, Darie CC, Woods AG.

J Neural Transm (Vienna). 2015 Aug;122 Suppl 1:S9-18. doi: 10.1007/s00702-013-1134-6. Epub 2013 Dec 20. Review.

PMID:
24357051
4.

[Diagnostic structured interviews in child and adolescent's psychiatry].

Renou S, Hergueta T, Flament M, Mouren-Simeoni MC, Lecrubier Y.

Encephale. 2004 Mar-Apr;30(2):122-34. Review. French.

PMID:
15107714
5.

Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry.

Lozupone M, Seripa D, Stella E, La Montagna M, Solfrizzi V, Quaranta N, Veneziani F, Cester A, Sardone R, Bonfiglio C, Giannelli G, Bisceglia P, Bringiotti R, Daniele A, Greco A, Bellomo A, Logroscino G, Panza F.

Expert Rev Proteomics. 2017 Sep;14(9):809-824. doi: 10.1080/14789450.2017.1375857. Epub 2017 Sep 11. Review.

PMID:
28870126
6.

Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.

Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, Roberts C, Hill E, Wiersma D, Bond GR, Huxley P, Tyrer P.

Health Technol Assess. 2001;5(21):1-75. Review.

7.

Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach.

Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N, Belanger E, James A, George S, Weber H, Graham DL, Schweitzer R, Ladd TB, Learman R, Niculescu EM, Vanipenta NP, Khan FN, Mullen J, Shankar G, Cook S, Humbert C, Ballew A, Yard M, Gelbart T, Shekhar A, Schork NJ, Kurian SM, Sandusky GE, Salomon DR.

Mol Psychiatry. 2015 Nov;20(11):1266-85. doi: 10.1038/mp.2015.112. Epub 2015 Aug 18.

8.

Translating biomarkers to clinical practice.

Perlis RH.

Mol Psychiatry. 2011 Nov;16(11):1076-87. doi: 10.1038/mp.2011.63. Epub 2011 Jun 28. Review.

9.

Role of proteomics in biomarker discovery: prognosis and diagnosis of neuropsychiatric disorders.

Patel S.

Adv Protein Chem Struct Biol. 2014;94:39-75. doi: 10.1016/B978-0-12-800168-4.00003-2. Review.

PMID:
24629185
10.

The Utility of Multiplex Assays for Identification of Proteomic Signatures in Psychiatry.

Chen J, Guest PC, Schwarz E.

Adv Exp Med Biol. 2017;974:131-138. doi: 10.1007/978-3-319-52479-5_8. Review.

PMID:
28353229
11.

How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression.

Macaluso M, Drevets WC, Preskorn SH.

J Psychiatr Pract. 2012 Jul;18(4):281-6. doi: 10.1097/01.pra.0000416018.83709.3e.

PMID:
22805902
12.

Can proteomics-based diagnostics aid clinical psychiatry?

Filiou MD.

Proteomics Clin Appl. 2015 Oct;9(9-10):885-8. doi: 10.1002/prca.201400144. Epub 2015 Apr 2.

PMID:
25619150
13.

How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction.

Macaluso M, Preskorn SH.

J Psychiatr Pract. 2012 Mar;18(2):118-21. doi: 10.1097/01.pra.0000413277.11091.25. Review.

PMID:
22418402
14.

Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary.

Wu R, Kemp DE, Sajatovic M, Zhao J, Calabrese JR, Gao K.

Clin Ther. 2011 Dec;33(12):B62-76. doi: 10.1016/j.clinthera.2011.11.013. Review.

PMID:
22177380
15.

Applications of blood-based protein biomarker strategies in the study of psychiatric disorders.

Chan MK, Gottschalk MG, Haenisch F, Tomasik J, Ruland T, Rahmoune H, Guest PC, Bahn S.

Prog Neurobiol. 2014 Nov;122:45-72. doi: 10.1016/j.pneurobio.2014.08.002. Epub 2014 Aug 27. Review.

PMID:
25173695
16.

Perfusion magnetic resonance imaging in psychiatry.

Théberge J.

Top Magn Reson Imaging. 2008 Apr;19(2):111-30. doi: 10.1097/RMR.0b013e3181808140. Review.

PMID:
19363433
17.

Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders.

Sethi S, Brietzke E.

Int J Neuropsychopharmacol. 2015 Oct 9;19(3):pyv096. doi: 10.1093/ijnp/pyv096. Review.

18.

Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.

Dager SR, Corrigan NM, Richards TL, Posse S.

Top Magn Reson Imaging. 2008 Apr;19(2):81-96. doi: 10.1097/RMR.0b013e318181e0be. Review.

19.

Immuno-psychiatry: an agenda for clinical practice and innovative research.

Leboyer M, Berk M, Yolken RH, Tamouza R, Kupfer D, Groc L.

BMC Med. 2016 Oct 28;14(1):173.

20.

New therapeutic promises in the treatment of depression and schizophrenia.

Dhir A, Kulkarni SK.

Drug News Perspect. 2008 Dec;21(10):581-92.

PMID:
19221639

Supplemental Content

Support Center